TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
CTOR

Citius Oncology, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

0.55$ -7.4% vs. previous close Closing price · As of: Nov 3, 2026

Ownership

Ownership Structure

Who owns Citius Oncology, Inc. (CTOR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 29.3% of the shares are freely tradable; institutional investors hold 15.3%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 15.3%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 79.6%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 29.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 106Mio.

Largest Shareholders

Institutions

Institutions CTOR
Name Stake (%) Shares Change (%) Date
Armistice Capital, LLC 8.23 8,705,589 -5.3 06/30/2026
Bank of America Corp 3.63 3,835,160 +0.0 06/30/2026
Vanguard Capital Management, LLC 0.52 546,325 +2.2 06/30/2026
UBS Group AG 0.32 334,619 +808.3 06/30/2026
Geode Capital Management, LLC 0.23 245,407 -7.3 06/30/2026
Vanguard Fiduciary Trust Co 0.12 121,910 +0.0 06/30/2026
IFP Advisors, LLC 0.10 107,424 +0.0 06/30/2026
Citadel Advisors Llc 0.09 90,586 +0.0 06/30/2026

Funds

Funds CTOR
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 0.35 370,100 +0.0 09/30/2026
Fidelity Extended Market Index 0.09 97,489 -0.5 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?